Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post‐authorization safety cohort study conducted in Europe and in the United States

• Véra EhrensteinAarhus University
• Kui A HuangPfizer (United States)
• Johnny A. KahlertAarhus University
• Shahram BahmanyarKarolinska University Hospital
• Pär KarlssonKarolinska University Hospital
• Lukas LöflingKarolinska University Hospital
• Anthony P. Nunes
• Cheryl L. Enger
• Irene D. BezemerPharmo Institute
• Josephina G. KuiperPharmo Institute
• Fabian J. Hoti
• Rosa Juuti
• Pasi A. Korhonen
• Jingping MoPfizer (United States)
• Stephen E. SchachterleCity University of New York
• Keith D. WilnerPfizer (United States)
• Mikael Rahbek RørthAarhus University
• Henrik Toft SørensenAarhus University